
Title: Viking Therapeutics (VKTX) Investor Relations
URL: https://ir.vikingtherapeutics.com/
Snippet: Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Key pipeline assets include VK2735 (GLP-1/GIP agonist) for obesity, VK2809 (TRb agonist) for NASH, and VK0214 for X-linked adrenoleukodystrophy.

Title: Viking Therapeutics Pipeline
URL: https://vikingtherapeutics.com/pipeline/
Snippet: Our pipeline includes:
1. VK2735: Dual GLP-1/GIP agonist (Phase 2 for Obesity).
2. VK2809: Thyroid Hormone Receptor Beta Agonist (Phase 2b for NASH).
3. VK0214: Thyroid Hormone Receptor Beta Agonist (Phase 1b for X-ALD).
4. VK1430: DGAT-1 Inhibitor (Preclinical).
5. VK2735 Oral: Oral formulation of GLP-1/GIP (Phase 1).

Title: Viking Therapeutics Corporate Overview
URL: https://vikingtherapeutics.com/corporate-overview/
Snippet: Viking is dedicated to developing novel treatments for metabolic diseases. We leverage our expertise in metabolism to create first-in-class or best-in-class therapies.
